

Chloe I Bloom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7796460/publications.pdf>

Version: 2024-02-01

47
papers

2,901
citations

331670

21
h-index

276875

41
g-index

49
all docs

49
docs citations

49
times ranked

5307
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Asthma Phenotypes and COVID-19 Risk: A Population-based Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 36-45. | 5.6 | 42 |
| 2 | First Maintenance Therapy for Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. <i>Pulmonary Therapy</i> , 2022, 8, 57-74. | 2.2 | 5 |
| 3 | Treatment Transitions in Chronic Obstructive Pulmonary Disease: Retrospective Analyses of US and UK Healthcare Databases. <i>Pulmonary Therapy</i> , 2022, 8, 75-93. | 2.2 | 2 |
| 4 | Accelerated FEV ₁ decline and risk of cardiovascular disease and mortality in a primary care population of COPD patients. <i>European Respiratory Journal</i> , 2021, 57, 2000918. | 6.7 | 24 |
| 5 | Inadequate specialist care referrals for high-risk asthma patients in the UK: an adult population-based cohort 2006–2017. <i>Journal of Asthma</i> , 2021, 58, 19-25. | 1.7 | 12 |
| 6 | Impact of health technology assessment on prescribing patterns of inhaled fixed-dose combination triple therapy in chronic obstructive pulmonary disease. <i>Journal of Market Access & Health Policy</i> , 2021, 9, 1929757. | 1.5 | 1 |
| 7 | Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. <i>Lancet Respiratory Medicine</i> , 2021, 9, 699-711. | 10.7 | 122 |
| 8 | Burden of preschool wheeze and progression to asthma in the UK: Population-based cohort 2007 to 2017. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1949-1958. | 2.9 | 30 |
| 9 | Considerations for conducting and interpreting long-term follow-up of intervention studies: avoiding spoiled milk. <i>Thorax</i> , 2021, 76, 1067-1068. | 5.6 | 0 |
| 10 | Decline in respiratory and cardiac admissions during the COVID-19 pandemic: What is the role of common respiratory virus infections?. <i>Respirology</i> , 2021, 26, 1010-1011. | 2.3 | 2 |
| 11 | Influence of the first wave of COVID-19 on asthma inhaler prescriptions. <i>Npj Primary Care Respiratory Medicine</i> , 2021, 31, 45. | 2.6 | 4 |
| 12 | Temporal trends in the incidence, treatment patterns, and outcomes of coronary artery disease and peripheral artery disease in the UK, 2006–2015. <i>European Heart Journal</i> , 2020, 41, 1636-1649. | 2.2 | 36 |
| 13 | Qualitative Study of Practices and Challenges of Stepping Down Asthma Medication in Primary Care Across the UK. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 429-437. | 3.4 | 3 |
| 14 | Health and cost impact of stepping down asthma medication for UK patients, 2001–2017: A population-based observational study. <i>PLoS Medicine</i> , 2020, 17, e1003145. | 8.4 | 19 |
| 15 | Asthma-Related Health Outcomes Associated with Short-Acting β_2 -Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. <i>Advances in Therapy</i> , 2020, 37, 4190-4208. | 2.9 | 66 |
| 16 | Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000756. | 3.0 | 17 |
| 17 | Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis. <i>Respiratory Research</i> , 2020, 21, 54. | 3.6 | 28 |
| 18 | Impact of comorbidities on peak troponin levels and mortality in acute myocardial infarction. <i>Heart</i> , 2020, 106, 677-685. | 2.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | <p>Inhaled Corticosteroid Treatment Regimens and Health Outcomes in a UK COPD Population Study</p>. International Journal of COPD, 2020, Volume 15, 701-710. | 2.3 | 10 |
| 20 | Temporal Trends in the Incidence of Heart Failure among Patients with Chronic Obstructive Pulmonary Disease and Its Association with Mortality. Annals of the American Thoracic Society, 2020, 17, 939-948. | 3.2 | 11 |
| 21 | Title is missing!. , 2020, 17, e1003145. | | 0 |
| 22 | Title is missing!. , 2020, 17, e1003145. | | 0 |
| 23 | Title is missing!. , 2020, 17, e1003145. | | 0 |
| 24 | Title is missing!. , 2020, 17, e1003145. | | 0 |
| 25 | Title is missing!. , 2020, 17, e1003145. | | 0 |
| 26 | Cost saving of switching to equivalent inhalers and its effect on health outcomes. Thorax, 2019, 74, 1078-1086. | 5.6 | 22 |
| 27 | <p>Changes in COPD inhaler prescriptions in the United Kingdom, 2000 to 2016</p>,. International Journal of COPD, 2019, Volume 14, 279-287. | 2.3 | 27 |
| 28 | Changing causes of death for patients with chronic respiratory disease in England, 2005-2015. Thorax, 2019, 74, 483-491. | 5.6 | 26 |
| 29 | Clinical profile of predefined asthma phenotypes in a large cohort of UK primary care patients (Clinical Practice Research Datalink). Journal of Asthma and Allergy, 2019, Volume 12, 7-19. | 3.4 | 6 |
| 30 | Predicting COPD 1-year mortality using prognostic predictors routinely measured in primary care. BMC Medicine, 2019, 17, 73. | 5.5 | 19 |
| 31 | Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006-2016. European Respiratory Journal, 2019, 53, 1802130. | 6.7 | 50 |
| 32 | Risk factors and secondary care utilisation in a primary care population with non-tuberculous mycobacterial disease in the UK. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 117-124. | 2.9 | 19 |
| 33 | Exacerbation Patterns in Adults with Asthma in England. A Population-based Study. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 446-453. | 5.6 | 63 |
| 34 | Low uptake of palliative care for COPD patients within primary care in the UK. European Respiratory Journal, 2018, 51, 1701879. | 6.7 | 66 |
| 35 | Exacerbation risk and characterisation of the UK's asthma population from infants to old age. Thorax, 2018, 73, 313-320. | 5.6 | 123 |
| 36 | Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza. Nature Immunology, 2018, 19, 625-635. | 14.5 | 119 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Hospitalisation and mortality outcomes of patients with comorbid COPD and heart failure: a systematic review protocol. <i>BMJ Open</i> , 2018, 8, e023058. | 1.9 | 3 |
| 38 | Nontuberculous mycobacterial disease managed within UK primary care, 2006–2016. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 1795-1803. | 2.9 | 16 |
| 39 | A 380-gene meta-signature of active tuberculosis compared with healthy controls. <i>European Respiratory Journal</i> , 2016, 47, 1873-1876. | 6.7 | 51 |
| 40 | The Transcriptional Signature of Active Tuberculosis Reflects Symptom Status in Extra-Pulmonary and Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2016, 11, e0162220. | 2.5 | 81 |
| 41 | HIV–tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling. <i>Nature Communications</i> , 2015, 6, 8451. | 12.8 | 81 |
| 42 | Identification of the Key Differential Transcriptional Responses of Human Whole Blood Following TLR2 or TLR4 Ligation In-Vitro. <i>PLoS ONE</i> , 2014, 9, e97702. | 2.5 | 17 |
| 43 | The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2014, 369, 20130427. | 4.0 | 75 |
| 44 | Systems approaches to studying the immune response in tuberculosis. <i>Current Opinion in Immunology</i> , 2013, 25, 579-587. | 5.5 | 41 |
| 45 | The Immune Response in Tuberculosis. <i>Annual Review of Immunology</i> , 2013, 31, 475-527. | 21.8 | 1,108 |
| 46 | Transcriptional Blood Signatures Distinguish Pulmonary Tuberculosis, Pulmonary Sarcoidosis, Pneumonias and Lung Cancers. <i>PLoS ONE</i> , 2013, 8, e70630. | 2.5 | 254 |
| 47 | Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy. <i>PLoS ONE</i> , 2012, 7, e46191. | 2.5 | 190 |